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1INTRODUCTION
Neurological complications occur in approximately 60% of patients
suffering from severe Chronic Kidney Disease (CKD), affecting the nervous
system at all levels, central as well as peripheral, yielding weakness,
prolonged disability and alteration of mental state.
 Amongst the many manifestations of  Uremia, the most common is uremic
neuropathy and its prevalence increases as Glomerular filtration rate (GFR)
decreases and also depends on the duration of the CKD and dialysis
therapy1,2.  Its  prevalence  is  about   60-  100%  in  those  on  dialysis 6,7.Even
though many patients may not have overt symptoms or signs, electro-
physiological  abnormalities in Nerve conduction studies may  be detected in
many patients indicating the presence of subclinical neuropathy. Uremic
neuropathy characteristically progresses over the course of months, but can
occasionally take a faster course, triggering a marked disability. It is
believed that Uremic neuropathy is caused by the accumulation of medium-
sized molecules that have not been adequately filtered.
 Even though regular maintenance Hemodialysis (HD)  slows the
progression of neuropathy, the abnormalities rarely improve or sometimes
they may worsen.
2However renal transplantation is associated with  rapid  improvement in
these neuro-physiological  abnormalities within days and clinical
improvement over months11.
3Aim of the study
 This study aims to evaluate the prevalence of peripheral neuropathy(both
overt and subclinical) in CKD stage -5 patients  on HD (particularly those on
transplant programme) through Nerve conduction studies and  to assess the
outcome of  neuropathy  after renal transplantation by follow-up  nerve
conduction studies at the end of first and third months.
4REVIEW OF LITERATURE
History
The existence of uremic neuropathy was first suspected by Charcot (1880)
and Osler (1892). Since the introduction of  hemodialysis(HD) and kidney
transplants in the early 1960s, uremic neuropathy has been studied in detail.
Asbury et al1,2 described the clinical and pathological characteristics in
detail.
The current concept of uremic neuropathy was established in 1971 by
Dyck3 and colleagues  in an extensive study of nerve conduction in vivo and
in vitro,  as well as in studies with light and electronic microscopy. Using
quantitative histology, they demonstrated axonal retraction: neuronal
dysfunction resulted in the decrease of axonal diameter, reorganization of
myelin and ultimately, complete degeneration of the axon.
Peripheral neuropathy develops in 60%- 90% of patients with end-stage
renal failure who require chronic dialysis 6, 7.
The development of neuropathy is determined by the degree of renal
impairment, with clinically significant neuropathy generally only occurring
after the glomerular filtration rate drops to less than 12 ml?minute.8
Severe uremic neuropathy has become less common as a result of earlier
treatment with dialysis and renal transplantation. Uremic neuropathy is
5more common in men than in women. The clinical features are those of a
slowly progressive, predominantly sensory polyneuropathy.
The major feature of length-dependent neuropathies, such as uremic and
diabetic neuropathies, is the greater involvement of those regions furthest
from the spinal cord, resulting in greater distal disease than proximal disease
and more severe involvement of lower limb nerves than upper limb nerves.
Severe pains are unusual, but cramps, unpleasant dysesthesias, and restless
legs are common symptoms. Muscle  cramps  of  the  distal  limbs  occur
commonly in uremic patients and many of these patients lack evidence of
neuropathy or tetany. Since cramps occur commonly in uremia. They
probably represent either shifts of fluids into muscle or the effects of uremic
toxins upon muscle or the neuromuscular junction12.
Clinical examination in the initial stages reveals changes that are confined to
the lower limbs, with reduction in ankle deep tendon reflexes and distal
(‘‘stocking’’) sensory loss. With more severe disease, motor involvement
develops, characterized by weakness and muscle atrophy, again most
prominent distally. With further progression, proximal regions of the lower
limbs are affected and upper limb involvement develops.10
Although the prevalence of severe neuropathy may appear to have lessened,
a significant cohort of ESRD patients still report symptoms which are
6functionally disabling, and even patients who meet accepted guidelines for
dialysis adequacy may complain of neuropathic symptoms .
Acute Uremic Neuropathy17
In addition, there is a more rapid (accelerated) process that has not been
widely appreciated as a cause of acute and subacute weakness. Most patients
were diabetics with stable ESRD who had been treated by peritoneal dialysis
for their long-standing kidney disease .In contrast to the better characterized
and less severe chronic  uremic neuropathy, generalized weakness and distal
paresthesias progress over 1 or more weeks until a bedbound state is
reached. The illness simulates subacute GBS. More aggressive dialysis or a
change to hemodialysis has little immediate effect, although kidney
transplantation is curative. Electrophysiologic studies show demyelinating
features (slowing of conduction velocity), but usually not a conduction
block. There is raised CSF protein concentration. A few reported cases have
responded to plasma exchange or gamma globulin. The cause of the acute
form is unknown.
Sub-acute  progressive motor neuropathy in diabetic patients with CKD
There is also a subacute progressive motor neuropathy which can occur in
diabetic patients with  CKD. Nerve conduction studies in these patients may
not demonstrate the features of a demyelinating neuropathy and
improvement has been noted with a switch from conventional to high-flux
dialysis, rather than with immunotherapy. The benefit of high flux dialysis in
7these patients has been  attributed to removal of advanced glycosylated end
products which have been implicated in the pathogenesis of both diabetic
neuropathy and nephropathy.
Small fiber neuropathy in CKD
While the clinical features of length-dependent uremic neuropathy reflect
damage to large sensory and motor fibers, a small fiber neuropathy may also
occur in CKD stage 5. Preferential damage to small fibers which carry pain
and temperature sensation may induce sensory symptoms dominated by
burning and painful dysaesthesiae. While objective changes in thermal
sensation have been reported, small fiber neuropathy is a far less common
presentation of uremic neuropathy and rarely occurs in the absence of large
fiber involvement.
Restless legs syndrome (RLS).
 Patients  with  RLS  describe  an  urge  to  move  their  legs,  typically  with
nocturnal exacerbation, due to the development of sensory symptoms which
worsen during periods of inactivity. The dysaesthesiae are either partly or
totally alleviated by the movements. Studies of RLS in ESRD patients have
demonstrated significant disruption to sleep, with resultant reduction in
quality  of  life.  The  distinction  between  RLS  and  neuropathy  is  critical  to
management, as patients with RLS may benefit from dopaminergic agents,
8including levadopa or dopamine agonists. A favorable therapeutic response
to these agents has led to the suggestion that central dopaminergic
dysfunction may play a role in the development of RLS, although other
processes such as hyperphosphatemia and iron deficiency have been linked
to symptom development in ESRD18 .
Diagnosis of Length-Dependent Uremic Neuropathy10
 The  initial  step  in  the  diagnosis  of  neuropathy  in  ESRD  patients  is  to
exclude other potential causes of neuropathy. Assessment for glucose
dysmetabolism is essential, both in view of the high rates of diabetes in
patients with ESRD and given that diabetic ESRD patients develop more
severe neuropathy. Patients who have rapidly progressive neuropathy require
further testing for connective tissue disorders which may be associated with
vasculitic neuropathy. Testing should include inflammatory markers,
antinuclear antibody, ANCA, Hepatitis antibodies (B and C),. Histological
studies should be considered before immunosuppressive therapy is
commenced, with combined nerve and muscle biopsies demonstrating
abnormalities in 60%of such cases.
9Nerve conduction studies remain the mainstay in the diagnosis of uremic
peripheral neuropathy.
With long-term  HD,  the neuropathic symptoms and signs stabilize . In fact,
rapid hemodialysis may worsen the polyneuropathy  temporarily. Peritoneal
dialysis appears to be more successful than hemodialysis in improving the
neuropathy but this observation has not been firmly established. Complete
recovery, occurring over a period of 6 to 12 months, usually follows
successful renal transplantation
Pathology  of Uremic neuropathy
Uremic neuropathy is one of a group of central-peripheral axonopathies, also
known as dying-back polyneuropathies. The clinical characteristics of such
distal  axonopathies  include the following:
? Insidious onset. In most human toxic neuropathies, there is a steady
low-level exposure. Because only the distal portion of selected,
scattered fibers is affected, the patient may still function well despite
the axonal degeneration.
? In all types of uremic polyneuropathies, pathologic changes are most
intense in the distal segments of the nerves with the expected
chromatolysis of their cell bodies.
? Onset in legs.
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? Large and long axons are affected early, and fibers of the sciatic nerve
are especially vulnerable
? Stocking-glove sensory loss. Degeneration in the distal axon proceeds
toward the cell body, resulting in clinical signs in the feet and hands
initially.
? Early loss of Achilles reflex. Fibers to the calf muscles are of large
diameter  and  among  the  first  affected  by  many  toxins,  even  when
longer, smaller-diameter axons in the feet are spared.
? Decrease  of  SNAP  and  CMAP   amplitude  with    normal  or  mild
slowing of motor nerve conduction
? Late responses (H-reflex and F-wave latencies) become abnormally
prolonged early in the course of chronic renal failure
? Normal CSF protein content.
? Pathologic changes are usually distal and nerve roots are spared.
? Slow recovery. Axonal regeneration (in contrast to remyelination) is
slow  about  1  mm  per  day.  Thus,  after  institution  of  dialysis  or  renal
transplantation, recovery of nerve function may take months or
years19.
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PATHOLOGICAL PATTERNS OF NEUROPATHY
The pathology of peripheral neuropathy follows three basic patterns:
Wallerian degeneration, distal axonopathy, and segmental demyelination.
Wallerian degeneration. The neuronal cell body maintains the axon
through the axoplasmic flow. When an axon is transected, its distal part,
including the myelin sheath, undergoes a series of changes leading to its
complete structural disintegration and chemical degradation.
Acute neuropathy Walleriandegeneration
Changes also occur in the neuronal body. The RER disaggregates and the
neuronal body balloons. The cytoplasm becomes smooth and the nucleus is
displaced toward the periphery of the cell. This process is called central
chromatolysis and reflects activation of protein synthesis in order to
regenerate the axon. Cytoskeletal proteins and other materials flow down the
axon.
In distal axonopathy, degeneration of axon and myelin develops first in the
most distal parts of the axon and, if the abnormality persists, the axon "dies
back". This causes a characteristic distal ("stocking-glove") sensory loss and
weakness.
12
Lipid material in
acute neuropathy
Axonal sprouts
Neurofilaments and organelles accumulate in the degenerating axon
(probably due to stagnation of axoplasmic flow). Eventually the axon
becomes atrophic and breaks down. Severe distal axonopathy resembles
Wallerian degeneration. At an advanced stage, there is loss of myelinated
axons.
Distal axonopathy is thought to be caused by pathology of the neuronal body
resulting in its inability to keep up with the metabolic demands of the axon.
This explains why the disease begins in the most distal parts of nerves, and
large axons that have the highest metabolic and nutritional demands are
more severely affected.
Segmental demyelination
It is characterized by breakdown and loss of myelin over a few segments.
The axon remains intact and there is no change in the neuronal body.
The loss of saltatory conduction that results from segmental demyelination
leads to decrease of conduction velocity and conduction block. Deficits
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develop rapidly but are reversible because Schwann cells make new myelin.
However, in many cases, demyelination leads to loss of axons and
permanent deficits. The nerve, in segmental demyelination, shows
demyelinated axons, thin-regenerating-myelin, "onion bulbs"  and in severe
cases, loss of axons. The status of myelin can be evaluated with teased fiber
preparations of peripheral nerves and by electron microscopy. Neuropathies
characterized by segmental demyelination include acute and
chronic inflammatory demyelinative neuropathies, diphtheritic neuropathy
metachromatic leuko-dystrophy and Charcot-Marie-Tooth disease.
                                          Hypertrophic neuropathy
"Onion bulb" formations are concentric layers of Schwann cell processes
and collagen around an axon. This proliferation is caused by repetitive
segmental demyelination and regeneration of myelin and can cause gross
thickening of peripheral nerves (hypertrophic neuropathy). The central
14
axon is often demyelinated or has a thin layer of myelin. Onion bulb
formations are the histological hallmark of Charcot-Marie-Tooth disease,
but are also seen in other hereditary neuropathies (Dejerine-Sottas disease,
Refsum disease), in diabetic neuropathy, and in chronic inflammatory
demyelinative neuropathy.
The pathology of peripheral neuropathy is reflected in the spinal cord. Acute
axonal neuropathy causes cental chromatolysis. Axonal neuropathy and
distal axonopathy involving the bipolar neurons of the dorsal root ganglia
cause degeneration of the central axons of these neurons in the gracile and
cuneate tracts of the spinal cord. This lesion is associated with loss of
position and vibration sense and sensory ataxia.
Neuropathies can be classified on the basis of their pathological changes
into axonal (Wallerian degeneration and distal axonopathy), demyelinative,
or mixed.
End stage axonal neuropathy
The pathological changes of most peripheral neuropathies (axonal
degeneration, segmental demyelination or a combination of these) are not
specific. In any active neuropathy, there are macrophages removing myelin
and axon debris.
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In most neuropathies, the sural nerve biopsy can only establish the diagnosis
of neuropathy and distinguish axonal from demyelinative and acute from
chronic neuropathy, but cannot determine the cause of neuropathy. Only a
few peripheral neuropathies show disease-specific pathological changes
allowing a specific diagnosis. These neuropathies include acute and chronic
inflammatory demyelinative neuropathies, hereditary motor and sensory
neuropathies, vasculitis, sarcoid neuropathy, leprosy, amyloid neuropathy,
neoplastic invasion of peripheral nerves, metachromatic leukodystrophy,
adrenomyeloneuropathy, and giant axonal neuropathy.
Pathophysiology
The cellular basis for distal axonopathies, however, remains unclear. What
has been called the "middle molecule" theory is possible9.  The end stage of
renal failure is associated with the accumulation of toxic substances in the
range of 300 to 12,000 kDa molecular weight such as. such as, creatinine,
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parathyroid hormone, myoinositol, and ?2-microglobulin . As is the case
with uremic encephalopathy, urea alone given to experimental animals and
in  controlled  studies  of  humans,  does  not  seem  capable  of  inducing  a
metabolic neuropathy. Spencer et al19. have emphasized that a number of
chemically unrelated neurotoxic compounds and several types of metabolic
abnormalities can cause strikingly similar patterns of distal symmetric
polyneuropathy in humans and animals. These authors suggest a possible
common metabolic basis for many distal axonopathies.  Neurotoxic
compounds may deplete energy supplies in the axon by inhibiting nerve
fiber enzymes required for the maintenance of energy synthesis. Resupply of
enzymes from the neuronal soma may fail to meet the increased demand for
enzyme replacement in the axon, causing the concentration of enzymes to
decrease in distal regions. This could lead to a local blockade of energy-
dependent axonal transport, which could then produce a series of pathologic
changes culminating distal nerve fiber degeneration.
Studies investigating the pathophysiology of neurological disease in CKD
have tended to focus largely on the hypothesis that one or more of these
retained toxins is responsible for mediating the neurological dysfunction.
This hypothesis has been supported by studies that demonstrated conduction
slowing in clinically unaffected nerve segments. These neuro-physiological
changes correlated with severity of renal impairment, and the clinical
symptoms and nerve conduction parameters were noted to improve rapidly
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following renal transplantation, often within days of surgery. the rapidity of
these changes suggests that toxin-mediated blockade of neural transmission
has an important role in the neuro logical dysfunction associated with CKD10
Five criteria have been proposed that should be met for a substance to be
considered as a uremic neurotoxin
Proposed criteria for a uremic neurotoxin
? Must be an identifiable chemical
? Should be elevated in the blood of patients with uremia
? A direct positive relationship should exist between blood level and
neurological dysfunction
? Should cause neurological dysfunction in experimental animals at
appropriate blood levels
? Removal from the blood should abolish the neurological dysfunction
on the basis of this framework.
Studies of uremic neuropathy have applied the rationale that bio chemical
alterations in CKD will result in dysfunction of the axonal membrane that
can be reversed with hemodialysis.
Several possible uremic toxins have been identified, which appear to be
correlated with depression of MNCV in laboratory animals23. However,
these studies do not take into account the fact that: (i) depressed MNCV is
cyclical, with abnormal low values one day and normal values the next; (ii)
there is a day-to-day variation in MNCV that approaches 20% 24 (iii) the
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finding of depressed MNCV in laboratory animals associated with high
plasma levels of potential uremic neurotoxins has generally not been
confirmed in human subjects with renal failure. Although it is possible to
relate impairment in MNCV with levels  in blood of various substances,  the
best correlation was obtained between reduced MNCV versus a reduction in
glomerular filtration rate.
Parathyroid Hormone25.26
Among the potential uremic neurotoxins is PTH, based on a possible
correlation  between  plasma  PTH  levels  and  MNCV  in  patients  with  CRF.
Although some earlier studies suggested a possible effect of PTH on MNCV
in the dog, these impressions have not been confirmed  In patients who have
hyperparathyroidism without uremia, PTH has no observable effect on
peripheral nerve function .
ROLE OF POTTASIUM AS A POTENTIAL NEUROTOXIN 10
While nerve conduction studies remain the gold standard for the clinical
assessment of neuropathy, they do not provide further insight into disease
pathophysiology. Recently, novel nerve excitability techniques, which
provide complementary information to nerve conduction studies, have been
adapted for clinical use. These studies have examined changes in nerve
function that occurred in ESRD patients before, during and after a single
19
session of hemodialysis. Measures of nerve function were also assessed in
relation to changes in serum levels of potential neurotoxins, including
potassium( K+), urea, and ‘‘middle-molecules" such as parathyroid hormone
and b2-microglobulin.
Using these novel excitability techniques, predialysis excitability
abnormalities were established to be strongly   correlated with serum K+ in
all studies.
Excitability studies also demonstrated that  abnormalities of nerve function
occurred at a level much lower than that required for cardiac toxicity, with
patients manifesting axonal changes with serum K+ concentrations in the
high  normal  range  (i.e.,4.9–5.0  mmol  ? l).  Following  dialysis  there  was
significant improvement although minor excitability abnormalities persisted,
suggesting that dialysis alone is insufficient in   normalizing nerve function.
In contrast, the strong correlations noted with serum K+ were not
demonstrated for any of the middle molecules. These findings are also
supported by studies that investigated the causes of weakness and fatigue in
ESRD, and demonstrated that abnormalities of K+ regulation may underlie
muscle fatigue and thereby contribute to exercise limitation in ESRD.
Potassium satisfies all the criteria that have been recently proposed for a
substance to be truly regarded as a uremic neurotoxin. It is an identifiable
chemical that is elevated in the serum of ESRD patients and causes
neurological dysfunction in both humans and experimental animals. It is also
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a critical determinant of axonal resting membrane potential.  Furthermore
excitability studies have demonstrated that a direct relationship exists
between serum levels of K+ and neurophysiological abnormalities and that
removal of K+ leads to improvement in nerve function.
Such persistent elevation in serum K+ would lead to chronic membrane
depolarization. It is well known that chronic changes in membrane potential
are harmful to axons and may trigger reverse activation of the Na+?Ca2+
exchanger, leading to an influx of Ca2+.Such processes may initiate a
cascade that eventually induces axonal death.
Role of Nerve Conduction Studies in diagnosing Uremic peripheral
neuropathy27
Nerve conduction studies remain the mainstay in the diagnosis of uremic
neuropathy. In length-dependent uremic neuropathy, nerve conduction
studies demonstrate features of a generalized neuropathy of the axonal type,
with reduction in sensory amplitudes and to  lesser extent, motor
amplitudes15,16 . Sensory and motor conduction velocities are relatively
preserved and needle   electromyography may reveal changes in denervation
in  distal  lower  limb  muscles.  In  patients  who  have  a  rapidly  progressive
course with significant weakness, the possibilities of demyelinating
neuropathy and accelerated  neuropathy of renal failure need to be
considered 17,28. Neurophysiological investigations in demyelinating
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neuropathies demonstrate significant reduction in conduction velocities,
often with preserved motor and sensory  amplitudes .29,30
Management of Length-Dependent Uremic Neuropathy
Renal transplantation remains the only cure for uremic neuropathy and must
be considered in any patient with progressive neuropathy11.
Neurophysiological improvement following renal transplantation is rapid,
often occurring within days31. Clinical recovery typically occurs over a
period of months, with neurological improvement occurring within 3–6
months in patients with mild neuropathy. A more delayed and often
incomplete improvement has been noted in patients with severe neuropathy,
with some patients only manifesting improvement after 2 years . While
modern dialysis regimens generally prevent progression of neuropathy,
clinical reversibility is uncommon11.
Rapidly progressive neuropathy, however, remains both an indication for the
commencement of dialysis therapy and an important indicator of insufficient
dialysis.  It  is  also  critical  to  ensure  that  patients  with  neuropathy  meet
current guidelines of dialysis adequacy and this may require an increased
frequency of dialysis. In some cases, a change to daily dialysis or high-flux
dialysis3  2may be beneficial as an interim measure in patients with severe
progressive neuropathy who are awaiting transplantation. This may confer
22
symptomatic benefits even   in patients who already meet conventional
targets for dialysis adequacy.
In patients with painful neuropathy, options for   symptomatic management
include the use of tricyclic antidepressants, such as amitriptyline, which have
proven efficacy in the treatment of neuropathic pain33. Of the anticonvulsant
medications, while sodium valproate continues to be used widely, newer
agents such as gabapentin are efficacious and well tolerated.
The potential role of hyperkalemia in uremic neuropathy raises the
possibility that dialyzing against a lower K+ concentration and attempting to
lower inter-dialytic K+ by ensuring strict dietary restriction of K+ may prove
beneficial, and randomized studies exploring this hypothesis are currently
underway. Certainly, the potential importance of K+ in length-dependent
uremic neuropathy may question the suitability of urea-based measures of
dialysis adequacy in determining the suitability of a dialysis regimen to
prevent neurotoxicity.
More recent studies suggest that, at least from a neuropathy perspective, a
better indication of adequate dialysis may relate to the maintenance of serum
K+ within normal limits between periods of dialysis.   Recent evidence
suggests that treatment with erythropoietin (EPO) may be beneficial for ESD
patients with neuropathy34. These studies have demonstrated
neurophysiological improvement following EPO treatment. Such findings
have been supported by studies which have demonstrated that EPO receptors
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on neural cells are upregulated after nerve injury in animal models and that
exogenous EPO administration is associated with reduction in limb
weakness and neuropathic pain behavior.
Other Neuropathies in CKD
Autonomic Neuropathy36:
Autonomic dysfunction is a common and potentially life-threatening
complication of CKD, and can occur in the absence of length-dependent
uremic neuropathy. Cardiovascular autonomic dysfunction in CKD is
associated with an  increased risk of cardiac arrhythmia and sudden cardiac
death.1Assessment of autonomic function has demonstrated abnormalities in
60% of patients with CKD, particularly relating to measures of
parasympathetic function, such as heart rate response to deep breathing,
induced hypotension, and the valsalva maneuver. Impotence remains the
most common symptom of  autonomic dysfunction in CKD, and it develops
in the majority of male patients. Other common clinical features include
bladder and bowel dysfunction, impaired  sweating, and orthostatic
intolerance. Arterial calcification might contribute to autonomic symptoms
in CKD by reducing the sensitivity of baroreceptors in the arterial  wall that
mediate the short-term regulation of blood pressure. In addition to a potential
role in sudden cardiac death, reduced baroreflex sensitivity can also
contribute to intra dialytic hypotension. Intradialytic hypotension is an
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independent risk factor for mortality in CKD, and its symptoms include
dizziness, blurred vision, cramps, nausea and vomiting. renal transplantation
leads to considerable improvement in autonomic function, whereas dialysis
treatments do not result in a substantial change37.
Compression neuropathies
Carpal tunnel syndrome may develop in more than 20% of patients on
hemodialysis. Nerve compression from local edema secondary to the
forearm arteriovenous shunts or ischemia from a  fistula induced vascular
steal syndrome are likely mechanisms in the early course of dialysis. Patients
on long-term hemodialysis may develop carpal tunnel syndrome because of
the deposition of  ?2-microglobulin-derived amyloid in the carpal ligament.
Ischemic monomelic neuropathy
It  is  an  acute  complication  of  the  placement  of  a  more  proximal  shunt
between the cephalic vein and brachial artery; the monomelic neuropathy
occurs mainly in diabetic patients with concomitant peripheral vascular
disease. It is characterized by abrupt, painful sensory loss of the affected
hand, and weakness of median, ulnar, and radial innervated distal muscles.
Prompt surgical closure of the fistula is   required to avoid permanent
neurological deficits.
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NERVE CONDUCTION STUDIES
Principles
Electrical stimulation of nerve fibers initiates impulses that   travel along
motor, sensory, or mixed nerves and evoke a compound action potential.
There are three types of Nerve conduction studies: motor, sensory, and
mixed.
Conduction characteristics of motor fibers are assessed indirectly by
studying the compound muscle action potential (CMAP) recorded from
the muscle; sensory fibers are assessed by analyzing the sensory nerve
action potential (SNAP) recorded from the nerve. Mixed Nerve
Conduction Studies assess directly the sensory and motor fibers
simultaneously by recording from mixed nerve action potential (MNAP).
The use of standard Nerve Conduction Studies allows precise lesion
localization and accurate characterization of peripheral nerve function.
Supramaximal  stimulation  of  a  nerve  that  results  in  depolarization  of  all
available axons is a paramount prerequisite to all NCS measurements. To
achieve supramaximal stimulation, current (or voltage) intensity is slowly
increased until it reaches a level at which the recorded potential docs not
increase. Then, the current should be increased an additional 20-30% to
ensure that the potential does not change further.
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Recording Electrodes
? Surface electrodes
? Needle electrodes
? Ring electrodes
Recording Procedure
A pre-pulse preceding the stimulus triggers the sweep on a storage
oscilloscope.
Motor Nerve Conduction Studies
Motor Nerve Conduction Studies are performed by stimulating a motor or
mixed peripheral nerve while recording the CMAP from a muscle innervated
by that nerve. A pair of recording electrodes consists of an active lead (Gl)
placed on the belly of the muscle and an indifferent lead (G2) on the tendon
(belly-tendon recording). The propagating muscle action potential,
originating under Gl located near the motor point, gives rise to a simple
biphasic waveform with initial negativity. Initial positivity suggests incorrect
positioning of the active electrode or a volume-conducted potential from
distant muscles activated by anomalous innervation or by accidental spread
of stimulation to other nerves. The nerve is stimulated at two or more points
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along its course. Typically, it is stimulated distally near the recording
electrode and more proximally to evaluate its proximal segment. Several
measurements are evaluated with motor Nerve Conduction Studies.
CMAP amplitude.
This is usually measured from baseline to negative peak and expressed in
millivolts. When recorded with surface electrodes, CMAP amplitude is a
semi quantitative measure of the number of axons conducting between the
stimulating and the recording points. CMAP amplitude also depends on the
relative conduction speed of the axons, the integrity of the neuromuscular
junctions, and the number of muscle fibers that are able to generate action
potentials.
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Motor nerve conduction study of the median nerve showing a typical compound muscle action
potential (CMAP) with distal and proximal stimulations, showing the distal and proximal
latencies and CMAP amplitudes, durations, and areas
CMAP duration.
This is usually measured as the duration of the negative phase of the evoked
potential and is expressed in milliseconds. It is a function of the conduction
rates of the various axons forming the examined nerve and the distance
between the stimulation and recording electrodes.
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Latencies:
This is the time interval between nerve stimulation (shock artifact) and the
onset  of  the  CMAP.  It  is  expressed  in  milliseconds  and  reflects  the
conduction rate of the fastest-conducting axon. Whenever it is technically
possible, the nerve is typically stimulated at two points: a distal point near
the recording site (distal latency) and a more proximal point (proximal
latency). Both latencies depend mostly on the length of the nerve segment
and, to a much lesser extent, on neuromuscular transmission time and
propagation time along the muscle membrane.
Conduction velocity:
This is a computed measurement of the speed of conduction and is expressed
in meters per second. Measurement of conduction velocity allows the
comparison of the speed of conduction of the fastest fibers between different
nerves and subjects, irrespective of the length of the nerve. It is calculated
after the length of the nerve segment is incorporated between distal and
proximal stimulation sites. The nerve length is estimated by measuring the
surface distance along the course of the nerve and should be more than 10
cm to improve the accuracy of surface measurement.
Distance
Motor conduction velocity=
        Proximal onset latency — Distal onset latency
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Sensory   Nerve Conduction Studies
Sensory axons are evaluated by stimulating a nerve while recording the
transmitted potential from the same nerve at a different site. Therefore,
SNAPs arc true nerve action potentials. Antidromic sensory Nerve
Conduction Studies are performed by recording potentials directed toward
the sensory receptors, whereas orthodromic studies arc obtained by
recording potentials directed away from these receptors. Sensory latencies
and conduction velocities are identical with either method, but SNAP
amplitudes generally are higher in antidromic studies. Because the
thresholds of some motor axons are similar to those of large myelinated
sensory axons, superimposition of action potentials from distal muscles may
obscure antidromically recorded SNAPs. Fortunately, latencies can still be
measured accurately because the large-diameter sensory fibers conduct 5-
10% faster than motor fibers. This relationship may change in disease states
that selectively affect different fibers.
SNAPs may be obtained by stimulating and recording a pure sensory nerve
(such as the sural and radial sensory nerves, stimulating a mixed nerve while
recording distally over a cutaneous branch (such as the antidromic median
and ulnar sensory responses), or stimulating a distal cutaneous branch while
recording over a proximal mixed nerve (such as the orthodromic median and
ulnar sensory studies). Similar to their motor counterparts, several
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measurements are recorded with sensory NERVE CONDUCTION
STUDIES.
SNAP amplitude:
This  is  a  semi  quantitative  measure  of  the  number  of  sensory  axons  that
conduct between the stimulation and recording sites. It is calculated from the
baseline to negative peak or from negative peak to positive peak and
expressed in microvolts.
Antidromic median sensory nerve conduction  study after stimulation at the wrist, revealing peak
and onset  latencies and sensory nerve action potential amplitude, duration, and area.
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Sensory Latencies:
With  sensory  Nerve  Conduction  Studies,  often  only  a  single   distal  site  is
stimulated. Sensory distal latencies may be measured (in milliseconds) from
the stimulus  artifact to the peak of the negative phase (peak  latency) or
from the stimulus artifact to the onset of the SNAP (onset latency).
Conduction velocity:
This requires stimulation at a single site only because the latency consists of
only the nerve conduction time from the stimulus point to the recording
electrode. It may be also done with distal and proximal stimulation sites.
Sensory conduction velocities are calculated similarly to their motor
counterparts; only onset latencies (not peak latencies) are used to calculate
the speed of the fastest conducting fibers.
Distance
Sensory conduction velocity=
        Proximal onset latency — Distal onset latency
The principal factors that influence the speed of NCV
? the integrity and degree of myelination of the largest diameter fibers;
? the mean cross sectional diameter of the responding axons;
? the representative intermodal distance in the segment under study;
? the micro environment at the nodes, including the distribution of ion
channels
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Physiological Variability and Common Sources of Error:
? Technical errors
? Temperature
? Age
? Height and Nerve Segment Lengths
? Anomalies
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MATERIALS AND METHODS
This study was conducted  from  August 2010  to December 2011 at
Department of Nephrology, Madras Medical college and Rajiv Gandhi
Government General Hospital, Chennai with active support from Neurology
Department.  The study protocol   was approved by the Ethics Committee of
the Government General Hospital and all subjects gave their informed
consent prior to the study.
Inclusion criteria
The study included 35 CKD stage V patients on Maintenance HD
(polysulfone dialyser, low flux) who were on Kidney transplantation
programme  (Live related) in our department.
Exclusion criteria
? Diabetes mellitus
? small vessel vasculitis
? systemic lupus erythematosus
? chronic alcoholic
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Methodology
All participants were assessed for the  presence of peripheral neuropathy by
eliciting detailed  history regarding symptoms of neuropathy, co-morbid
illness,  history of alcohol intake, drug intake, duration of CKD and period
of Hemodialysis(HD).
Detailed neurological examination was performed to assess presence of
decreased touch, pain, temperature, vibration and position sensations and
motor abnormalities like decreased  power and deep tendon reflexes(DTR)
in the extremities.
Routine investigation include urine analysis, complete hemogram, Blood
Urea, serum creatinine, Electrolytes, Liver function tests,Viral Markers and
Thyroid function tests.
All these patients were on supplemental doses of vitamin B complex during
the period of study
All patients were subjected to Nerve conduction studies (motor and sensory
of both upper and lower limbs). It was done immediately after a HD session
so that patients were oedema free.
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Electrodiagnostic Measures-Standardization
The Electro diagnostic protocol, as recommended by AAEM was used.
Neuro-physiological studies were performed by RECORDERS and
MEDICARE SYSTEMS EMG. EP MARK – II, EMG machine, a 4channel
electrophysiological device.
Recommended filter settings (approximate values) were 20-3,000 Hz band-
pass for sensory studies, 2-10,000 Hz band-pass for motor studies.
The temperature of the room was maintained at 22-24oC during all processes
Standardized nerve conduction techniques were used. Conventional methods
using surface electrodes for motor conduction and ring electrodes for
sensory conduction were used
Nerve Conduction Studies in the lower limbs.
In the lower limbs sensory conduction in sural nerve (SNAP- sensory nerve
action potential)   and motor conductions in tibial nerves(CMAP-
Compound Muscle action potential)  were done bilaterally in all the patients.
Nerve Conduction Studies in upper limbs
 Nerve conduction studies in the upper limbs included sensory (SNAP) and
motor(CMAP) conductions of median nerve.
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In the Median nerve Nerve conduction studies were done in the non AV
fistula arm and in those  patients who did not have  an AVF it was done on
the dominant arm (Right).
None of the patients had symptoms or signs of carpal tunnel syndrome.
COMPONENTS ASSESSED:
? Distal Latency (DL)
? Proximal latency
? Amplitude:
? Nerve conduction velocity (NCV)
THE FOLLOWING PARAMETERS WERE MEASURED
? Sural nerve- Amplitude, CV, DL of SNAP
? Tibial nerve- Amplitude, CV, DL of CMAP
? Median nerve - Amplitude, CV, DL of SNAP and CMAP
Protocol for electro diagnostic test:
The normal values for representative nerve conduction values at various sites
of stimulation were derived at after analyzing the nerve conduction studies
of 20 age matched patients who came to Neurology OPD for complaints
other than neuropathy.
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Normal values
Sensory nerve conduction studies(SNAP)
Nerve Amplitude(mv) CV(m/s)
Distal
Latency(ms)
Sural >6 >40 <4.4
Median >5 >50 <3.5
Motor nerve conduction studies(C MAP)
Nerve Amplitude(mv) CV(m/s)
Distal
Latency(ms)
F wave
latency(ms)
Median >4.2 >49 <4.2 <30
Tibial >4.1 >41 <6 <56
Based on the results the patients were divided into two groups
Group 1- patients who had clinical or electrophysiological evidence of
neuropathy
Group 2- patients who had no clinical or electrophysiological evidence of
neuropathy
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The  parameters  (SNAP,  CMAP)  were  analyzed  to  assess  whether  it’s  a
axonopathic (? amplitude,  ? conduction velocities , ? distal latency)  or
demyelinating (normal amplitude, ? CV ,? Latency).
They were further divided into predominantly sensory, motor or mixed
sensorimotor involvement or predominant lowerlimb  or upperlimb or
involvement of both limbs.
Those patients in group 1 who had clinical or Neuro-physiological evidence
of neuropathy underwent follow-up  nerve conduction studies in Post renal
transplant period at the end of 1st and 3rd months.
The parameters mentioned above were measured again and the results were
compared with the pre-transplant values and analyzed for statitistical
significance.
Statistical analysis was done using SPSS software using repeated measures
ANOVA  test.
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OBSERVATION & RESULTS
The study included 35 participants (CKD Stage 5 patients) on Hemodialysis
(HD) and on live related  kidney transplantation programme. 30 patients (24
males;  6  females)  completed  the  study.  (5  people  had  either  died  or  lost  to
follow up).
Native kidney disease among participants
Male Female
Chronic
Glomerulonephritis
8 3
Chronic Interstitial
nephritis
4
CAKUT 1
Not known 12 1
Acute cortical necrosis 1
Pre-tranplant  clinical  examination:
Of the thirty patients, 8 (26.6%)(7M:1F) had clinical evidence of peripheral
neuropathy. The main symptoms were  paresthesiae or  dysesthesiae of  feet
(burning sensation , tingling, pins and needles, or cramp-like sensations) and
or  numbness.
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On neurologic examination these patients had symmetrical decreased
vibration sense in the toes  and ankle and also ?temperature and  superficial
pain sensations in the feet. Six (20%) patients had decreased ankle jerk.
None of them had restless leg syndrome, weakness, wasting, spontaneous
disabling  pain in the limbs or sensory ataxia.
All   30  underwent   nerve  conduction  studies  in  the  pre-  transplant  period.
On  nerve  conduction  studies   20(66.7%)   patients  showed  evidence   of
peripheral neuropathy.
{8  symptomatic and 12 asymptomatic patients(subclinical neuropathy)}.
Sex ratio
Female
Male
0
1
2
3
4
5
6
7
8
No Neuropathy
Subclinical
neuropathy Clinical
neuropathy
2
2
2
8 8
6
Female
Male
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Influence of  duration  of CKD and of dialysis on neuropathy
Mean age in years of patients & status of neuropathy
0
5
10
15
20
25
No Neuropathy
Subclinical
neuropathy Clinical
neuropathy
8.3
13.5
21.5
6.5
10.8
16.12
Mean duration of CKD in
months
Mean duration of
dialysis in months
23.6
28.5
36.2
0
5
10
15
20
25
30
35
40
No Neuropathy Subclinical neuropathy Clinical neuropathy
Mean age in years
Mean age in years
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Clinical profile
All 20 patients who had clinical or subclinical neuropathy underwent repeat
nerve conduction studies after successful renal transplantation at the end of
1st and 3rd months.
Parameter No
neuropathy
Sub Clinical
neuropathy
Clinical
neuropathy
No 10 12 8
M:F 8:2 10:2 6:2
Mean age in years 23.6 28.5 36.2
Mean duration of
CKD in months
8.3 13.5 21.5
Mean duration of
dialysis in months
6.5 10.8 16.12
HCV 2 1
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Results of nerve conduction studies
Neuropathy sensory Sensorimotor
Lower limb alone 7 1
Both lowerlimb and
upperlimb
3 9
Patterns of neuropathy
0% 50% 100%
sensory
Sensorimotor
7
1
3
9
Lower limb alone
Both lowerlimb and
upperlimb
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RIGHT SURAL NERVE (SENSORY NERVE ACTION POTENTIAL)
The sural nerve  SNAP was obtained successfully in 26 subjects (86.6%).
16/26(61.53%)  patients had abnormal SNAP in the pre-transplant period.
Follow-up results of these 16 patients were analysed
In  4(13.3%)  patients   sural  nerve  SNAP   was  absent  bilaterally  in
pretransplant period, but were included in the follow-up study
Parameter PRE TX
( A )
POST T X
1 month (B) p valueA vs B
POST TX
3 month(C ) p valueA vs C
p value
B vs C n
Distal
latency ms
mean(sd)
3.570
(0.71)
2.963
(0.6562)
>.05 2.527
(0.4776)
<.05 >.05
 16
Amplitude
in mv
mean(sd)
4.831
( 0.7846)
5.913 (1.060) <.05 7.213
(1.244)
<.05 >.05
conduction
velocity
mean(sd)
38.275
(1.541)
46.758
(4.715)
<.05 54.217
(8.220)
<.05 >.05
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LEFT SURAL NERVE SNAP
In the pre-transplant nerve conduction studies 61.43% had involvement of
sural   nerve  bilaterally.  It  was  associated  with  ? amplitude  of  SNAP? or?
Conduction velocity and a near normal distal latency (an axonopathic
pattern).
The follow up study showed there is increase in SNAP conduction velocity,
Amplitude of  sural nerves bilaterally.
Parameter PRE TX
( A )
POST T X
1 month
(B)
p value
A vs B
POST TX
3 months
(C )
p
value
A vs C
p value
B vs C
n
Distal
latency  in
ms
mean(SD)
3.606
(1.056)
3.136
(1.470)
>.05 2.528
(0.5468)
<.05 >.05
16
Amplitude
in mv
mean(SD)
5.188
(0.447)
5.981
(0.7195)
<.05 7.057
(1.058)
<.05 <.05
conduction
velocity
mean(SD)
38.350
(1.637)
46.874
(3.741)
<.05 54.706
(4.820)
<.05 >.05
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RIGHT  TIBIAL NERVE CMAP
The tibial nerve CMAP was obtained successfully in all the patients.
10 patients had abnormalities in pre-transplant CMAP of tibial nerve
bilaterally of axonopathic type. Follow-up data were analyzed for these ten
patients and compared.
Parameter Pre tx( A )
Post t x
1 mon (B )
p value
A vs B
Post tx
3 mon (C ) p valueA vs  C
p value
B vs C n
Distal
latency ms
mean(sd)
4.050
(1.70)
3.722
(0.5842)
>.05 3.323
0.7278
>.05 >.05
10
Amplitude
in mv
mean(sd)
3.690
(0.3213)
4.320
(0.6630)
>.05 5.150
(0.9277)
<.05 <.05
Conduction
velocity
m/s
mean(sd)
42.344
(5.449 )
47.079
(5.605)
>.05 48.890
(3.816)
<.05 >.05
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LEFT  TIBIAL NERVE CMAP
The same 10  patients  had  abnormalities  in  pre-transplant  CMAP of   of  left
tibial nerve.
These data show there is significant increase in CV and amplitude and a
non-significant  decrease in distal latency.
Parameter Pre tx
( A )
Post tx
1 month
(B)
p value
A vs B
Post tx
3 months (C )
p value
A vs C
p value
B vs C
n
Distal
latency ms
mean(sd)
3.689
(1.204)
3.613
(0.5815)
>.05 3.066
(0.6917)
>.05 >.05
10Amplitude
in mv
mean(sd)
3.820
(0.1932)
4.3
(0.6498)
>.05 5.270
(1.197)
<.05 <.05
conduction
velocity
mean(sd)
40.1
(1.897)
47.938
(5.104)
<.05 49.212
(4.955)
<.05 >.05
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MEDIAN NERVE SNAP
11 patients had abnormal nerve conduction studies  in median nerve SNAP
values in the pre-transplant period.  It showed ? amplitude, ? conduction
velocities , ? distal latency. Follow-up data of these 11 patients analyzed. It
was associated with improvement in electrophysiology (? in CV and
amplitude).
Parameter Pre tx( A )
Post t x
1 month (B )
p value
A vs B
Post tx
3 mon (C ) p valueA vs C
p value
B  vs C n
Distal
latency ms
mean(sd)
2.073
(0.5176)
1.994
(0.3525)
>.05 2.132
(0.4039)
>.05 >.05
11
Amplitude
in mv
mean(sd)
4.636
(0.3802)
5.318
(0.3430)
<.05 6.264
(0.6562)
<.05 >.05
Conduction
velocity
mean(sd)
48.351
(2.729)
59.653
(5.051)
<.05 64.784
(5.041)
<.05 >.05
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MEDIAN NERVE CMAP
6 patients had abnormal nerve conduction studies  in Median nerve CMAP
values in the pre-transplant period.  Follow-up data of these 6patients
analyzed. It also showed increased amplitude, CV & decreased latency in the
post –transplant period .
Parameter pre tx
( A )
post t x
1 mon (B )
p value
A vs B
post tx
3 mon (C )
p value
A vs C
p value
B vs C
n
Distal
latency ms
mean(sd)
3.098
(0.7223)
2.915
(0.3122)
>.05 2.892
(0.3158)
>.05 >.05
6
Amplitude
in mv
mean(sd)
4.0
(0.0894)
4.383
(0.2483)
<.05 5.833
(0.3724)
<.05 >.05
conduction
velocity
m/s
mean(sd)
51.605
(3.837)
55.563
(5.169)
>.05 61.358
(6.399)
<.05 >.05
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DISCUSSION
In  this  study  of  30  patients,  only  8  had  symptoms  /  signs  of  peripheral
neuropathy (overt) whereas another 12 had   nerve conduction studies
evidence of neuropathy (subclinical)
The clinical neuropathy group is associated with relatively older age(36.2
vs28.5y)  longer period of CKD( 21.5 vs 13.5 m) and dialysis(16.1vs
10.8m).
 Those patients in group 1(neuropathic) had only relatively mild symptoms
and  signs  when  compared  to  earlier  studies.  This  could  be  to  initiation  of
Renal Replacement Therapy (RRT) earlier, shorter duration of dialysis and
earlier kidney transplantation.
None  of  the  patients  in  our  cohort  had  restless  leg  syndrome.  This  is  in
discordance with earlier literature ( Ekbom KA et al),which show it was very
common  in  among  dialysis  patients.  This  may  be  due  to  shorter  period  of
dialysis and CKD  in our cohort which  may account for the lower incidence.
One patient in group 1 had Hepatitis C  infection in the pre-transplant period.
However his Serum cryoglobulin was negative.
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SENSORY NERVE CONDUCTION STUDIES
In the pre-transplant nerve conduction studies 61.43% had involvement of
sural  nerve bilaterally. It was associated with ? amplitude of SNAP,? or?
Conduction velocity and a near normal distal latency (an axonopathic
pattern).
In 4(13.3%) patients sural nerve SNAP was absent bilaterally in pre-
transplant period. It is possible that the inability to record a distal sural SAP
with surface electrodes may represent early changes of an as yet subclinical
neuropathy, or  it resulted from the difficulty in distinguishing a low
amplitude SAP from noise.
However the nerves could be stimulated in the post transplant period and the
neurophysiological parameters (?amplitude, ?Conduction velocity)
improved between the two  NCS done in the post-transplant period. Hence it
was most likely due to neuropathic involvement. .
Of all lower limb sensory nerves only the sural provides such a ready index
of lower limb sensory function. Sensory conduction studies in lower limb
nerves have a higher percentage yield in polyneuropathy than such studies in
upper limb nerves in concordance with  David burke, et al35.
Post-transplant studies in sural nerve SNAP showed increasing amplitudes
and CV between pretransplant and post-transplant 3 months values(p <.05)
53
In  the  upper  limb  SNAP  of   Median  nerve  showed  axonal  type  of
involvement in 11 (36.6%)  patients. Its is associated with CMAP
abnormalities in 6(20%) patients.
Following  transplant  there  is  there  is  an  ? in  amplitude  and  CV between  0
and 3 months (p<.05) .
MOTOR NERVE CONDUCTION STUDIES
Tibial  and median nerves CMAP   showed  abnormalities  of axonopathic
type in 10(33.3%)and  6(20%) patients, respectively. These patients  also
had  associated   sensory  nerve   involvement.  Post  transplant  there  is  an
improvement in  neuro-physiological parameters with increase in amplitude,
CV  and decrease in latency(ns).
None of the patients had motor nerve involvement without sensory
involvement.
Our study correlates with earlier studies in that involvement in uremic
neuropathy  is a “dying back" axonal neuropathy with distal symmetrical
involvement  and  length-dependent polyneuropathy, in which the it is that
the neurons that have the longest axons  appear to be the first to be affected
similar to that what was observed. by  Dyck PJ, et al3
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It also concords that there is predominant  sensory involvement, with lower
limb involved much more than upper limb as have been described by
Spencer and Schaumberg et al26.
The earlier electrophysiological improvement seen in CV  and amplitude
(CV>Amplitude) may be due to segmental  remyelination followed by
axonal recovery as suggested as by Bolton, C. F., et al11
The almost invariable improvement of neuropathy after transplantation is
due to clearance of “Middle molecules” such as methyl guanidine and
myoinositol,  which  has  been  shown  to  correlate  with  the  degree  of
neurotoxicity. These toxins (and the clinical signs of neuropathy) are not
greatly reduced by hemodialysis.
The most commonly affected parameter in the present study was sural
SNAP  amplitude,  which  was  abnormal  in  a  higher  percentage  of  patients
than   median   SNAP  amplitude,  consistent  with  the  lower  limb
predisposition of neuropathy similar to the study by  Arun V. Krishnan, et al
Based on individual patients NCS in post –transplant period  we divide them
into two cohorts
? Cohort 1- Nerve conduction studies parameters improved
? Cohort 2- Nerve conduction studies parameters worsened or no
change
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Parameter Cohort 1 Cohort 2 p value
No 17 3 ns
M:F 13:4 3:0 ns
Age in years 30.4 37.3 ns
Duration of CKD
in months
16.3 18.6 ns
Duration of HD
in months
11.4 18.5 P< .05
The only statistically significant association in cohort 2 is duration of HD. It
probable that the axonapathy  may take a longer time to recover. A follow-
up study at 6,12 and 24 months would give a answer.
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CONCLUSIONS
1. Peripheral neuropathy in CKD is common and its prevalence increases
with duration of CKD and Hemodialysis.
2. Many patients may not have overt symptoms but nerve conduction studies
can detect abnormalities.
3. It is a predominantly distal symmetrical sensory or sensorimotor
neuropathy   (sensory>motor) with lower limb involved more than upper
limb.
4. Its predominantly axonal polyneuropathy with secondary demyelination.
5. Post renal transplantation there is improvement in conduction velocity and
amplitudes earlier due to segmental remyelination.
6. In some patients recovery may take a longer time.
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LIMITATIONS OF OUR STUDY
? Our cohort is small (30 patients)
? Male and females are not equally represented.
? NKD is not known in many patients.
? We have not ruled out ANCA negative vasculitis, heavy metal
poisoning Amyloidosis as the cases of CKD (or) neuropathy.
? The follow up period is short (3 months post transplant)
The neurotoxic side effects of CNI s (Tacrolimus or Cyclosporine)on long
term neurological recovery is not known
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APPENDIX 2- PROFORMA
A STUDY OF PERIPHERAL NEUROPATHY IN CHRONIC KIDNEY
DISEASE STAGE -5  AND   IT’S OUTCOME AFTER KIDNEY
TRANSPLANTATION
NAME AGE
SEX NC
ADDRESS & CONTACT NO
NKD
CKD     - DURATION
STAGE
DURATION  OF DIALYSIS
COMORBID CONDITIONS:
DIABETES     DURATION
HYPERTENSION     DURATION
PERSONAL HISTORY:
ALCOHOLISM
SMOKING
DRUG HISTORY:
SYMPTOMS OF      PARAESTHESIA
    TINGLING
PINS & NEEDLES
HYPOESTHESIA (REDUCTION  IN SENSE OF PRESSSURE, LIGHT
TOUCH,WARMTH & COLD)
HYPERESTHESIA
HYPALGESIA
ALLODYNIA
GLOVE &STOCKING SENSORY LOSS
WEAKNESS
RESTLESS LEGS
EXAMINATION
PULSE
BLOOD PRESSURE
-SUPINE STANDING
HIGHER CEREBRAL FUNCTIONS
CONSCIOUSNESS
ORIENTATION
MEMORY
SENSORY SYSTEM:
LIGHT TOUCH
PRESSURE
TEMPERATURE
WARM
COLD
PAIN
VIBRATION
 JOINT POSITION SENSE
MUSCULOSKELETAL  SYSTEM
TONE
POWER
REFLEXES
SUPERFICIAL:
DTR    -BICEPS
TRICEPS
SUPINATOR
KNEE
ANKLE
COORDINATION
GAIT
INVESTIGATIONS
INFORMATION SHEET
We are conducting a study, “A study of Peripheral Neuropathy in CKD
and its outcome after renal Transplantation” among patients attending
Government General Hospital, Chennai.
The purpose of this study is to analyse the prevalence, clinical presentation
of  Peripheral  neuropathy  in  CKD stage  V patients  & to  assess  its   outcome after
renal transplantation .
When you are being evaluated for renal transplantation (with or without
overt signs of peripheral neuropathy) we will include you in this study with your
consent.
We may be using you to perform extra tests and special studies which in any
way do not affect your final report or management.
The privacy of the patients in the research will be maintained throughout the
study. In the event of any publication or presentation resulting from the research,
no personally identifiable information will be shared.
Taking part in this study is voluntary. You are free to decide whether to
participate in this study or to withdraw at any time; your decision will not result in
any loss of benefits to which you are otherwise entitled.
The  results  of  the  special  study  may  be  intimated  to  you  at  the  end  of  the
study period or during the study if anything is found abnormal which may aid in
the management or treatment.
Signature of investigator  Signature of participant
NERVE CONDUCTION STUDY
CMAP
Nerve Latency Amplitude Conduction
Velocity
SNAP
Nerve Latency Amplitude Conduction
Velocity
